Anlotinib significantly prolonged median progression-free survival (PFS) (hazard ratio [HR] = 0.15, 95% CI: 0.04–0.51; p = 0.0005) and median OS (HR = 0.26, 95% CI: 0.09–0.73; p = 0.0061) in SCLC patients with BM.
In this post hoc analysis of a multicenter, randomized, double-blind, placebo-controlled trial, anlotinib demonstrated a potential survival benefit in small cell lung cancer (SCLC) with brain metastases (BM) compared with placebo, with manageable toxicity. Anlotinib significantly prolonged median progression-free survival (PFS) (hazard ratio [HR] = 0.15, 95% CI: 0.04–0.51; p = 0.0005) and median OS (HR = 0.26, 95% CI: 0.09–0.73; p = 0.0061) in SCLC patients with BM.